Drug Profile
Sotirimod
Alternative Names: R-850; S-30594Latest Information Update: 21 Jul 2015
Price :
$50
*
At a glance
- Originator 3M Pharmaceuticals
- Developer Meda
- Class Antineoplastics; Naphthyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Actinic keratosis
Most Recent Events
- 21 Jul 2015 No recent reports on development identified - Phase-II for Actinic keratosis in Europe (Topical)
- 17 Aug 2012 Phase II development is ongoing in the European Union
- 31 Dec 2009 Phase-II clinical trials in Actinic keratosis in Europe (Topical)